Evidence map›Paper›PMID 18989460›Full record

ArticlePLoS pathogens2008

Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway.

Jianhua Sui, Daniel R Aird, Azaibi Tamin, Akikazu Murakami, Meiying Yan, Anuradha Yammanuru, Huaiqi Jing, Biao Kan, Xin Liu, Quan Zhu and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Genomic Surveillance of SARS-CoV-2 Variants in the Dominican Republic and Emergence of a Local Lineage.International journal of environmental research and public health · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. The virological impacts of SARS-CoV-2 D614G mutation.Journal of molecular cell biology · 2021
    Review
  15. SARS-CoV-2 Variants of Concern.Yonsei medical journal · 2021
    Review
  16. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Jianhua SuiDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Jianhua_sui@dfci.harvard.edu
Daniel R Aird
Azaibi Tamin
Akikazu Murakami
Meiying Yan
Anuradha Yammanuru
Huaiqi Jing
Biao Kan
Xin Liu
Quan Zhu
Qing-An Yuan
Gregory P Adams
William J Bellini
Jianguo Xu
Larry J Anderson
Wayne A Marasco
Harvard University · USNational Institute for Communicable Disease Control and Prevention · CNDana-Farber Cancer Institute · USCenters for Disease Control and Prevention · USFox Chase Cancer Center · USNational Center for Infectious Diseases · US

Funding

Human Antibodies and Targeted Vaccines Against SARS-CoVU01AI061318 · NIAID · DANA-FARBER CANCER INSTITUTE · PI MARASCO, WAYNE A. · 2004 to 2008
$3.6M
NIAID NIH HHS U01 AI061318NIAID NIH HHS U01-AI061318
6 · The paper itself

Abstract

Phylogenetic analyses have provided strong evidence that amino acid changes in spike (S) protein of animal and human SARS coronaviruses (SARS-CoVs) during and between two zoonotic transfers (2002/03 and 2003/04) are the result of positive selection. While several studies support that some amino acid changes between animal and human viruses are the result of inter-species adaptation, the role of neutralizing antibodies (nAbs) in driving SARS-CoV evolution, particularly during intra-species transmission, is unknown. A detailed examination of SARS-CoV infected animal and human convalescent sera could provide evidence of nAb pressure which, if found, may lead to strategies to effectively block virus evolution pathways by broadening the activity of nAbs. Here we show, by focusing on a dominant neutralization epitope, that contemporaneous- and cross-strain nAb responses against SARS-CoV spike protein exist during natural infection. In vitro immune pressure on this epitope using 2002/03 strain-specific nAb 80R recapitulated a dominant escape mutation that was present in all 2003/04 animal and human viruses. Strategies to block this nAb escape/naturally occurring evolution pathway by generating broad nAbs (BnAbs) with activity against 80R escape mutants and both 2002/03 and 2003/04 strains were explored. Structure-based amino acid changes in an activation-induced cytidine deaminase (AID) "hot spot" in a light chain CDR (complementarity determining region) alone, introduced through shuffling of naturally occurring non-immune human VL chain repertoire or by targeted mutagenesis, were successful in generating these BnAbs. These results demonstrate that nAb-mediated immune pressure is likely a driving force for positive selection during intra-species transmission of SARS-CoV. Somatic hypermutation (SHM) of a single VL CDR can markedly broaden the activity of a strain-specific nAb. The strategies investigated in this study, in particular the use of structural information in combination of chain-shuffling as well as hot-spot CDR mutagenesis, can be exploited to broaden neutralization activity, to improve anti-viral nAb therapies, and directly manipulate virus evolution.

Indexed as

Biological EvolutionSelection, GeneticAICDA (Activation-Induced Cytidine Deaminase)AnimalsAntibodies, ViralComplementarity Determining RegionsCytidine DeaminaseEpitopesHumansImmune SeraSevere acute respiratory syndrome-related coronavirusAICDA (Activation-Induced Cytidine Deaminase)Antibodies, ViralComplementarity Determining RegionsCytidine DeaminaseEpitopesImmune Sera

Identifiers

PMID18989460
PMCPMC2572002
OpenAlexW1970636382

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.